Ortho Biotech Products L.P. (label), 2008-11-19: The November 2008 Procrit label carries the strengthened boxed warning that ESAs shortened survival or increased tumour progression/recurrence in several cancers, and restricts use to anaemia from myelosuppressive chemotherapy.
ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers
PDF p.1 (boxed warning, 'Cancer' paragraph)
Ortho Biotech Products L.P. (label), 2008-11-19: The November 2008 Procrit label carries the strengthened boxed warning that ESAs shortened survival or increased tumour progression/recurrence in several cancers, and restricts use to anaemia from myelosuppressive chemotherapy. This is the 2007-2008 boxed-warning action the book refers to, quoted from the label dated the day of approval (11-19-08), revised 08/2008 in the body. Regulatory text: no funder/COI; maker Ortho Biotech (J&J). Same label adds 'ESAs are not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure.' The current label (Epogen, revised 12/2024) retains the same warning. Study type: regulatory record.
